miércoles, 5 de noviembre de 2025

Sarepta Therapeutics’ dismal quarter marred by drug failures and a long list of excuses CEO deflects blame for company’s setbacks

https://www.statnews.com/2025/11/04/sarepta-therapeutics-duchenne-trials-earnings/

No hay comentarios: